

# **A Joint Regional Chapter Meeting with SCCSOT and the Critical Path Institute**

***Topic: Translational Safety in Drug Development  
– Innovations and Challenges***

**Venue: Pfizer, La Jolla, CA**

**Date: October 16, 2014**

Time	Activity	Speaker
8:00-9:00	Reception/Breakfast	
9:00-9:10	Welcome and Introduction	SCCSOT President
9:10-9:50	Translational Safety in Drug Development: The role of safety biomarkers in predictive toxicology	John-Michael Sauer, PhD (C-Path)
9:50-10:30	Two-Year Rodent Cancer Bioassay: Human Relevance?	Sam Cohen, MD, PhD (UNMC)
10:30-10:50	BREAK	
10:50-11:30	Drug-Induced Cardiovascular Effects across Species	Jon Heyen, PhD (Pfizer)
11:30-11:50	Non-rodent Kidney Toxicity Biomarkers	J. Eric McDuffie, MBA, PhD (Janssen)
11:50-1:00	LUNCH	
1:00-1:40	The AMG 009 Story: An Opportunity to Improve Translational Safety Assessment	Ryan Morgan, PhD (Amgen)
1:40-2:10	Translational Safety Assessment of 2'-MOE Antisense Oligonucleotides Using Non-Clinical and Clinical Safety Database Mining	Husam Younis, PharmD, PhD (ISIS)
2:10-2:20	BREAK	
2:20-3:10	Preclinical Development of Neurotoxicity Biomarkers using MRI	Serguei Liachenko, MD, PhD (FDA)
3:10-3:30	Roundtable discussion	John-Michael Sauer, PhD (C-Path)
3:30-5:00	RECEPTION/Poster Sessions	
4:45-5:00	Announce student winners of the poster sessions	SCCSOT President